Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
The historical rank and industry rank for DaShenLin Pharmaceutical Group Co's Net Current Asset Value or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of DaShenLin Pharmaceutical Group Co was 40.87. The lowest was 13.22. And the median was 30.18.
SHSE:603233's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.94 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
DaShenLin Pharmaceutical Group Co (SHSE:603233) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
DaShenLin Pharmaceutical Group Co Net Current Asset Value Related Terms
DaShenLin Pharmaceutical Group Co Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co Net Current Asset Value Chart
DaShenLin Pharmaceutical Group Co Net Current Asset Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co Price-to-Net-Current-Asset-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of ¥-4.46 mean?
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a Net Current Asset Value of ¥-4.46 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. Over the past decade, DaShenLin Pharmaceutical Group Co's Net Current Asset Value has ranged from 13.22 to 40.87. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #999999 out of 269 companies in the Healthcare Providers & Services industry.
Is DaShenLin Pharmaceutical Group Co's Net Current Asset Value too high?
DaShenLin Pharmaceutical Group Co's current Net Current Asset Value is ¥-4.46. Over the past 10 years, this metric has ranged from a low of 13.22 to a high of 40.87. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #999999 out of 269 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's Net Current Asset Value compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #999999 out of 269 companies for Net Current Asset Value. This places DaShenLin Pharmaceutical Group Co in the lower half of its industry. The industry median Net Current Asset Value is 5.94. Historically, DaShenLin Pharmaceutical Group Co's own Net Current Asset Value has ranged from 13.22 to 40.87 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Healthcare Providers & Services company?
The median Net Current Asset Value among Healthcare Providers & Services companies is 5.94, based on 269 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. For the Healthcare Providers & Services industry, the median Net Current Asset Value is 5.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaShenLin Pharmaceutical Group Co's current Net Current Asset Value is ¥-4.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.88, compared to a current price of ¥18.98 — trading 0.5% above its estimated fair value. The current Net Current Asset Value is ¥-4.46. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current Net Current Asset Value is ¥-4.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥18.98 is trading 0.5% above its estimated GF Value™ of ¥18.88.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603233:
Net Current Asset Value: ¥-4.46
GF Value™: ¥18.88 vs. price of ¥18.98 (0.5% above fair value)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Business Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
93GF Score
Get the complete analysis for SHSE:603233
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
